Berubicin hydrochloride is under clinical development by CNS Pharmaceuticals and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Berubicin hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Berubicin hydrochloride overview
Berubicin hydrochloride (RTA 744) is under development for the treatment of glioblastoma, recurrent glioblastoma multiforme, CNS lymphoma, breast cancer, lung cancer, malignant glioma, pediatric brain tumor, pancreatic cancer, high grade gliomas, ovarian cancer and lymphomas. The drug candidate is an anthracycline derivative. It is a lyophilized drug product administered intravenously. It is a potent inhibitor of topoisomerase II. The drug circumvent ATP-binding cassette transporters(multidrug resistance protein 1, breast cancer resistance protein, P-glycoprotein). It was also under development for the treatment of metastatic breast cancer, brain metastasis, anaplastic astrocytoma, anaplastic mixed oligo-astrocytoma, anaplastic oligodendroglioma, neoplastic meningitis (leptomeningeal carcinomatosis) and malignant glioma.
CNS Pharmaceuticals overview
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specialized in developing novel medicines for brain tumours. It carries out research and development operation in matters related to various cancer treatments and related drugs. The company offers anticancer drug treatment for brain and central nervous system tumors. CNS Pharmaceuticals product portfolio includes Berubicin and WP1244. The company’s products find application in various therapeutic areas such as treatment for glioblastoma, brain tumor and other related concerns. It is also involved in developing treatment for pancreatic and ovarian cancers. The company has obtained patent from Houston Pharmaceuticals as well as collaborated with Reata Pharmaceuticals for developing its pipeline products. CNS Pharmaceuticals is headquartered in Texas, the US
For a complete picture of Berubicin hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.